Pioneers like Alnylam Pharmaceuticals have led the RNA interference field for years. Now, a crop of young biotechs is ...

Quantiphi Global Head of Healthcare and Life Sciences Barinder Marhok said the partnership marries DDReg’s expertise in ...

Just three years removed from a lucrative IPO, the company will cut jobs for a third time and invest more heavily in cell ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

Per terms, Novo could pay up to $285 million in upfront and milestone fees to Ascendis, which specializes in a kind of ...

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett ...

For a small rare disease company with a treatment in the clinic, the toughest challenge isn’t necessarily the science. Often, ...

The quality of digital PCR data can only be as high as the assays used to obtain it. High-quality assays ensure that the ...

The biotech expects three Phase 2 readouts in urticaria and eczema over the next two years, and will keep its “options open” ...

The Phase 3 findings position semaglutide to become the first drug of its kind for the liver disease. But they also confirm ...

Patient advocates are hoping for change under new director Michelle Tarver, while industry groups hope she will build on ...